Skip to main content
Clinical Trials/NCT00137293
NCT00137293TerminatedPhase 2

A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486

Wyeth is now a wholly owned subsidiary of Pfizer7 sites in 2 countries30 target enrollmentStarted: November 1, 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Terminated
Sponsor
Enrollment
30
Locations
7
Primary Endpoint
This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.

Study Overview

Brief Summary

The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Double

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion Criteria

  • Patients with uncontrolled blood pressure
  • Patients with certain cardiac risk factors
  • Patients with significant kidney or liver problems

Outcomes

Primary Outcomes

This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.

Secondary Outcomes

  • This study takes place within 24 hours, and looks at the changes in values of electrophysiology studies, before and after administration of test article.

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor Class
Industry

Study Sites (7)

Loading locations...

Similar Trials